Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

CONCLUSIONS: TMB is negatively associated with clinical outcomes in metastatic EGFR mutant lung cancer patients treated with EGFR-TKI. This relationship contrasts with that seen in lung cancers treated with immunotherapy.
PMID: 30045933 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 25, 2018 Category: Cancer & Oncology Authors: Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD Tags: Clin Cancer Res Source Type: research